description) Narcolepsy-cataplexy is a sleep disorder affecting 0.05% of the general population in the US. The development of narcolepsy involves environmental factors on a specific genetic background. The importance of environmental factors can be illustrated by the fact that 25-31% of monozygotic twins reported in the literature are discordant for narcolepsy. One of the predisposing genetic factors is located in the MHC DQ region. Eighty-five to 100 percent of all patients share a specific HLA allele, DQB1+0602 versus 12-38% of the general population in various ethnic groups. Genetic factors other than HLA are also likely to be involved. Even if genuine multiplex families are rare, 1-2% of the first degree relative of a patient with narcolepsy are affected by the disorder. These investigators have found a few multiplex families with numerous affected members and no apparent haplotype linkage with HLA. Studies using a canine model of the disorder also illustrate the importance of non MHC genes in disease predisposition. In this model, narcolepsy is transmitted as a single autosomal recessive trait (canarc-1) unlinked with MHC class II polymorphisms. A solid linkage marker for canarc-1 has been identified (current LOD score=15.3 at 0% recombination). In this project, a positional cloning approach will be used in both canines and humans to isolate novel narcolepsy susceptibility genes. Forty-eight multiplex families with narcolepsy-cataplexy and a microsatelite marker genome scanning experiment will be used to determine human genomic segments containing narcolepsy susceptibility genes. In canines, a large insert (BAC) library will first be constructed. This resource will be used to build genomic contigs and to develop new polymorphic markers around the previously identified canine narcolepsy gene marker. They will then saturate susceptibility regions in both canines and humans with polymorphic markers to narrow down the region containing candidate narcolepsy genes. Candidate genes will then be isolated and tested using high throughput genomic sequencing and other molecular techniques until disease susceptibility genes are identified. This group believes this approach will reveal the cause of narcolepsy and open new therapeutic avenues for the disorder.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL059601-03
Application #
6056476
Study Section
Special Emphasis Panel (ZHL1-CSR-R (S1))
Project Start
1997-09-30
Project End
2001-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Stanford University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Okun, Michele L; Lin, Ling; Pelin, Zerrin et al. (2002) Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 25:27-35
Hungs, M; Fan, J; Lin, L et al. (2001) Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 11:531-9
Lin, L; Hungs, M; Mignot, E (2001) Narcolepsy and the HLA region. J Neuroimmunol 117:9-20
Hungs, M; Lin, L; Okun, M et al. (2001) Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 57:1893-5
Mignot, E (2001) A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacology 25:S5-13
Hungs, M; Mignot, E (2001) Hypocretin/orexin, sleep and narcolepsy. Bioessays 23:397-408
Overeem, S; Mignot, E; van Dijk, J G et al. (2001) Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18:78-105
Peyron, C; Faraco, J; Rogers, W et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991-7
Nevsimalova, S; Vankova, J; Sonka, K et al. (2000) [Hypocretin (orexin) deficiency in narcolepsy-cataplexy] Sb Lek 101:381-6
Nishino, S; Ripley, B; Overeem, S et al. (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39-40

Showing the most recent 10 out of 12 publications